Image 2_COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.pdf
Introduction<p>Chronic myeloid leukemia (CML) is a severe hematological malignancy characterized by BCR-ABL fusion gene. The advent of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL has improved the landscape of CML treatment dramatically. The occurrence of coronavirus disease 2019 (COVID...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!